Connect with us


NEWS

GOODNEWS: New HIV Drug Eliminates 99% Of Virus Within Four Weeks — Israeli Coy

Published

on

Zion Medical, an Israeli biotech company developing HIV and cancer treatments, has announced the results of the first clinical trial of HIV-drug Gammora, eliminating up to 99 percent of the HIV virus within four weeks of treatment.

Investigational Medicinal Product Gammora is a synthetic peptide compound derived from the HIV enzyme integrase, which is responsible for inserting the virus’s genetic material into the DNA of the infected cell.

Gammora stimulates the integration of multiple HIV DNA fragments into the host cell’s genomic DNA, to an extent that triggers the self-destruction of the infected cell, called apoptosis.

The peptide, produced by San Diego, California-based PolyPeptide Labs, has the potential to cure HIV infected patients, by destroying all cells carrying the HIV virus-genome.

This is opposed to the commercially available retroviral treatments, the so-called “cocktail,” which merely suppresses the spreading of the virus, but do not cure the infection.

Between July and August 2018, Zion Medical conducted a Phase 1/2a human clinical trial of Gammora, reaffirming results of prior preclinical tests that had shown the safety and effectiveness of the drug in killing HIV-infected cells.

In the Part I of this trial, nine HIV-infected patients at the Dr. Ronald Bata Memorial Hospital in Entebbe, Uganda, were randomly assigned to receive either 0.05-0.2 mg/kg, or 0.1- 0.3 mg/kg, or 0.2-0.4 mg/kg of Gammora for up to four weeks to five weeks.

Most patients showed a significant reduction of the viral load of up to 90 percent from the baseline during the first four weeks.

In Part II of the study, conducted two weeks after the first, patients were given Gammora with additional retroviral treatment combined for another four weeks to five weeks.

Patients received either commercially available lopinavir 800 mg and ritonavir 200 mg (LPV+r) daily in combination with Gammora 0.2-0.4 mg/kg given twice a week, or LPV+r only.

The results found that combined-treated patients demonstrated sustained viral suppression and achieved HIV-1 RNA <300 copies/mL, and showed up to 99 per cent reduction in viral load from baseline within four weeks.

Through the 10 weeks, patients in both studies demonstrated that Gammora is a safe and well-tolerable drug, exhibiting no side effects.

Patients showed a significant increase of the CD4 cell count – up to 97 percent from the baseline.

CD4 cells, also referred to T cells or T helper cells, play an important role in the body’s immune system and are an indicator of its overall health.

“These first clinical results were beyond our expectations and promise hope in finding a cure for a disease that’s been discovered over 35 years,” says Dr. Esmira Naftali, head of development at Zion Medical. “Given the limited nature of this study, we are excited to prove the efficiency of our drug in Phase 2b with a greater number of participants over a longer period of time.”

Abraham Loyter, professor at the Hebrew University of Jerusalem, first started research on this novelty drug about 10 years ago, having been granted patents for the peptide in 2015 and 2017 (U.S. Patent No. 9163067, 9738878).

Zion Medical in-licensed the compound and has been continuing research and development through pre-clinical and clinical stages, building an entire team of researchers around the development of Gammora.

On August 31, 2018, Zion Medical filed another patent application with the US Patent and Trademark Office for an updated version of the peptide and final drug composition.

New York City’s Mount Sinai Hospital has collaborated with Zion in earlier stages of development and might partner with the company again in the future.

The company hopes to start Phase 2b in the coming months, involving around 50 patients that are given Gammora over two to three months.

Israel-based Zion Medical was established in 2014 with the mission to develop groundbreaking medical solutions for HIV/AIDS and cancer.

It is known for its patented synthetic peptide Gammora, which is derived from the HIV enzyme integrase and has been proven to be effective in killing HIV-infected cells, and which has also shown promising results with some types of cancers cells.

PR Newswire.

Advertisement

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

BIG STORY

JUST IN: Again, Police Arrest Speed Darlington During Show In Imo State

Published

on

Operatives of the Nigeria Police Force have arrested Nigerian musician Darlington Okoye, popularly known as Speed Darlington, in Owerri, the capital of Imo State.

The singer’s counsel and human rights lawyer, Deji Adeyanju, confirmed the arrest in a post on his official X page on Wednesday.

Adeyanju revealed that his client was detained while performing at a show in Owerri, just days after returning to Nigeria earlier in the week.

He wrote, “Our client, Speed Darlington, a.k.a AKPI, has been arrested by the Nigeria Police in Owerri at his show upon return to Nigeria.”

However, the exact reason for the singer’s arrest remains unclear at the time of filing this report.

It is worth noting that the Nigeria Police had previously arrested Darlington over allegations of cyberstalking fellow musician Damini Ogulu, better known as Burna Boy.

Darlington was initially arrested in Lagos, then transferred to Abuja, where he was detained by the IGP’s Intelligence Response Team in the Guzape area of the city.

The musician, who faced accusations of cyberstalking Burna Boy, was later released on bail days after his arrest.

Continue Reading

BIG STORY

President Tinubu Asks NNPC To Fast-Track Reactivation Of Warri, Kaduna Refineries

Published

on

President Bola Tinubu has praised the Nigeria National Petroleum Company (NNPC) Limited for the revitalization of the Port Harcourt refinery.

On Tuesday, NNPCL announced the official commencement of crude oil processing at the refinery—a milestone achieved after three years of rehabilitation work.

In a statement on Tuesday from Bayo Onanuga, the president’s special adviser on information and strategy, Tinubu urged the NNPC to expedite the reactivation of the Warri and Kaduna refineries.

Tinubu, while acknowledging the efforts of former President Muhammadu Buhari in making this achievement possible, reaffirmed his administration’s commitment to advancing energy sufficiency in Nigeria.

“The President acknowledges the pivotal role of former President Muhammadu Buhari in initiating the comprehensive rehabilitation of all our refineries and expresses gratitude to the African Export-Import Bank for its confidence in financing this critical project,” the statement reads.

“Furthermore, President Tinubu commends the leadership of NNPC Limited’s Group Chief Executive Officer, Mr. Mele Kyari, whose unwavering dedication and commitment were instrumental in overcoming challenges to achieve this milestone.

“With the successful revival of the Port Harcourt refinery, President Tinubu urges NNPC Limited to expedite the scheduled reactivation of both the second Port Harcourt refinery and the Warri and Kaduna refineries.”

Tinubu emphasized that the commencement of petrol production at the refinery would bolster the country’s domestic production and position Nigeria as a major energy hub.

He called on individuals, institutions, and citizens entrusted with public infrastructure to uphold trust in their service to the nation.

“These efforts will significantly enhance domestic production capacity alongside the contributions of privately-owned refineries and make our country a major energy hub, with the gas sector also enjoying unprecedented attention by the administration,” Onanuga said.

“In alignment with the Renewed Hope Agenda focused on shared economic prosperity for all, the President reaffirms his administration’s commitment to achieving energy sufficiency, enhancing energy security, and boosting export capacity for Nigeria.”

Continue Reading

BIG STORY

FG Considering US Diaspora Bond, Targets $1bn Monthly Remittances — CBN Governor Cardoso

Published

on

Olayemi Cardoso, governor of the Central Bank of Nigeria (CBN), announced that the country’s foreign reserves increased to $40.88 billion as of November 21.

Cardoso made the statement on Tuesday during a press conference following the monetary policy committee’s 298th meeting in Abuja.

He reported that the external reserves grew from $40.06 billion at the end of October to $40.88 billion in November.

This marks an increase of $82 million, or 2.05 percent, in just 21 days.

“The external reserves rose marginally to 40.88 billion as of 21 November 2024, from 40.06 billion at the end of October 2024, available to finance 17 months of imports,” he explained.

However, a check on the apex bank’s website revealed that Nigeria’s foreign reserves were listed at $40.27 billion on November 22, which is lower than the figure presented by Cardoso.

Further commenting on the matter, Cardoso stated, “the process of getting us where we are in terms of reserves has been a long one.”

“It is a clear indication that the policies we have put in place are certainly yielding fruits,” he added.

He emphasized that “reserves are there for a multiplicity of different purposes, not least of which is to create buffers in the event of unanticipated shocks.”

“They are not there to simply whittle away. They are there to be used to more or less defend yourself where that becomes necessary,” he clarified.

“And when we talk about shocks that are not anticipated, I think we can see how the global economies are,” Cardoso continued.

The governor also affirmed that the bank will persist in efforts to stabilize the currency and prices.

“The currency has been stable compared to what it was in June,” he noted.

However, he pointed out that for the country’s currency to maintain stability, there must be increased exports and greater diversification of the economy.

Cardoso also highlighted that diaspora remittances have risen due to policies that have been implemented.

He commended Nigerians in the diaspora for helping the country achieve over $600 million in remittances.

Continue Reading



 

Join Us On Facebook

Most Popular